Cibus Inc (NASDAQ:CBUS) Reports Q3 2025 Earnings Miss on Revenue, Narrower Loss

Last update: Nov 14, 2025

Cibus Inc (NASDAQ:CBUS) reported its financial results for the third quarter of 2025, delivering figures that fell short of analyst expectations on the top line while showing a narrower-than-expected loss per share. The market's immediate reaction reflected disappointment, with the stock declining significantly in after-hours trading.

Earnings and Revenue Versus Estimates

The company's performance during the quarter presented a mixed picture when measured against Wall Street forecasts. While the bottom-line loss was less severe than anticipated, revenue generation failed to meet projections.

Earnings Per Share (EPS): Cibus reported a non-GAAP net loss of $0.44 per share. This compared favorably to the analyst consensus estimate for a loss of $0.53 per share.
Revenue: The company posted revenue of $0.62 million for the quarter. This fell substantially short of the $1.42 million that analysts had been expecting, representing a significant miss on the top line.
Market Reaction: Following the earnings release, Cibus shares traded down approximately 8% in after-hours action. This price movement suggests investor focus was centered on the revenue shortfall and the company's liquidity position, overshadowing the improved EPS figure.

Financial Health and Liquidity Position

Beyond the quarterly earnings miss, the company's balance sheet and cash position remain a critical focal point. Cibus reported a cash and cash equivalents balance of $23.9 million as of September 30, 2025. The company stated that, after accounting for cost-saving initiatives and without any new financing, this capital is expected to fund operations into early in the second quarter of 2026. Management also noted that the Board of Directors is actively evaluating strategic alternatives to maximize shareholder value, a common disclosure when a company is seeking to bolster its financial standing.

Business Progress and Strategic Updates

Despite the financial headlines, the company's press release detailed significant operational progress across its key programs, particularly in its core Rice trait development.

Rice Trait Commercialization: Cibus has now signed seven customer agreements for its Rice herbicide tolerance traits. The company estimates these partnerships represent 5-7 million addressable acres and a potential royalty opportunity exceeding $200 million annually upon full development. The first commercial launch in Latin America remains on track for 2027.
Global Expansion: The quarter saw the addition of the Centro Internacional de Agricultura Tropical (CIAT) as a customer, bringing the total to five Rice customers in Latin America. The company also engaged a strategic advisory firm to support its entry into the Indian rice market.
Operational Efficiency: Cibus continues to execute on cost-saving initiatives, consolidating its Oberlin facility into its San Diego headquarters. The company is targeting a reduced annual net cash usage of $30 million by 2026.
Pipeline Advancements: Positive field trial results were reported for the HT2 trait in Canola, and pre-commercial pilot runs for biofragrance products were successfully completed, with commercial expansion targeted for 2026.

Looking Ahead

The provided analyst estimates for the upcoming quarter and full year set a benchmark for future performance. For the fourth quarter of 2025, the consensus estimates are for a loss of $0.56 per share on revenue of $1.59 million. For the full 2025 year, analysts are projecting a loss of $2.69 per share with revenue of $5.02 million. The press release from Cibus did not provide its own financial outlook for these periods to compare against these estimates.

For a detailed history of Cibus' earnings and future analyst estimates, you can review the data here.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. The information presented is based on publicly available data and should not be relied upon as the sole basis for an investment decision.